WO2000071160A1 - Compositions medicinales contenant un anticorps anti-fas - Google Patents
Compositions medicinales contenant un anticorps anti-fas Download PDFInfo
- Publication number
- WO2000071160A1 WO2000071160A1 PCT/JP2000/003324 JP0003324W WO0071160A1 WO 2000071160 A1 WO2000071160 A1 WO 2000071160A1 JP 0003324 W JP0003324 W JP 0003324W WO 0071160 A1 WO0071160 A1 WO 0071160A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibody
- fas
- diamino
- pharmaceutical composition
- glutamic acid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
- C07C279/24—Y being a hetero atom
- C07C279/26—X and Y being nitrogen atoms, i.e. biguanides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
- C07D475/08—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Definitions
- the present invention relates to a novel pharmaceutical composition effective for preventing or treating an autoimmune disease or rheumatoid arthritis.
- apoptosis physiological cell death that occurs due to normal cell replacement is called apoptosis, and is distinguished from necrosis (necrosis), which is a pathological cell death (Kerr, et al. (1972) Br. J. Cancer 26, 239).
- necrosis a pathological cell death
- programmed cell death is the death of certain types of cells that are programmed to die in vivo in advance, and apoptosis is one of them.
- apoptosis phenomena such as cell surface curvature, nuclear chromatin condensation, and chromosomal DNA fragmentation are specifically observed.
- Apoptosis plays a role in the differentiation of lymphocytes (T cells and B cells) by eliminating cells that recognize self antigens.
- autoimmune diseases are caused by the generation of autoreactive lymphocytes due to defective apoptosis in lymphocyte differentiation (see Keiichi Nakayama et al. (1995) Mebio 12 (10), 79-86).
- Examples of molecules involved in such apoptosis include Fas [see Yonehara, S. et al. (1989) J. Exp. Med. 169, 1747-1756], and tumor necrosis factor receptor i> 1 umor Necrosis Factor Receptor; [See Loetscher, H. et al. (1990) Cel 161, 351-359], CD40 [Tsubata, T. et al.
- Fas is a transmembrane protein that exists on the cell surface and is a protein called Fas ligand. Binds to its extracellular region and induces apoptosis in the cell. It has been reported that some anti-Fas monoclonal antibodies have cytotoxic activity that induces cell apoptosis, similar to Fas ligand, and can be used as a therapeutic agent for autoimmune diseases, AIDS and tumors. (Refer to Japanese Patent Application Laid-Open No. 2-2377935 and Japanese Patent Application Laid-Open No. 5-503282).
- Rheumatoid arthritis is a disease based on synovial cell proliferation with various immunological abnormalities caused by external and external factors. It is thought to be a synovial cell proliferation disorder with invasion and bone erosion. Tissue destruction of the affected joints in rheumatoid arthritis is thought to be caused by abnormal production of cytokines from inflammatory synovial cells. Examination of the condition of the joints of rheumatoid patients reveals that synovial cells are abnormally proliferating and that synovial villi are growing and synovial cells are multi-layered (Daniel J.
- the present invention relates to a pharmaceutical composition
- a pharmaceutical composition comprising, as active ingredients, an anti-human Fas antibody having an apoptosis-inducing activity and a compound having a folate antagonism or a dihydrofolate reductase inhibitory activity.
- the anti-human Fas antibody is a monoclonal antibody
- the compounds having an antifolate activity or dihydrofolate reductase inhibitory activity include methotrexet, edatrexet, epiroprim, iometrexol, pyritrexime, trimetrexate, brodimoprim, MX-68, N-[4- [3- (2,4-Diamino-6,7-dihydro-5H-cyclopentapenta [d] pyrimidin-5-yl) propyl] benzoyl] -L-glutamic acid, N- [[[[3- (2,4-Diamino-6,7-dihydro-5H-cyclopentapenta [d] pyrimidin-5-yl) propyl] benzoyl] -L-glutamic acid, N- [[[[3- (2,4-Diamino-6,7-dihydro-5H-cyclopentapenta [d] pyrimidin-5-yl) propyl] benzoyl] -L-glutamic
- apoptosis-inducing activity refers to an activity that can induce an apoptosis of a cell by binding to the Fas of a cell that expresses Fas on the cell membrane surface.
- the anti-human Fas antibody used as the first active ingredient of the pharmaceutical composition of the present invention may be any as long as it can specifically bind to human Fas and has apoptotic induction activity.
- an anti-human Fas antibody preferably, an anti-human Fas monoclonal antibody CHI1 and an anti-human Fas produced by mouse-mouse hybridoma HFE7A (FERMBP-58828)
- monoclonal antibody HFE7A or a humanized antibody thereof European Patent Publication No. 0990916
- Recombinants of these anti-human Fas monoclonal antibodies also have the same effects as these monoclonal antibodies, and are included in the anti-human Fas monoclonal antibody of the present invention.
- the anti-Fas monoclonal antibody has been modified by genetic recombination technology so as to reduce immunogenicity in humans without impairing the binding ability to Fas or the apoptosis-inducing activity of the anti-Fas monoclonal antibody.
- a so-called humanized antibody can also be used.
- a compound having an antifolate action or an inhibitory action of dihydrofolate reductase refers to a pharmacologically active substance which has an activity of antagonistically inhibiting folate metabolism, which is an essential process in intracellular DNA synthesis. Refers to an acceptable compound.
- the compounds described below can be mentioned:
- the pharmaceutical composition of the present invention comprises an anti-Fas monoclonal antibody having an activity of inducing apoptosis in cells expressing Fas, and a compound having an antifolate activity or an inhibitor of dihydrofolate reductase. Can be obtained by formulating a mixture of the above as appropriate.
- Anti-Fas monoclonal antibodies can be produced by methods well known in the art, for example, using a molecule containing the extracellular region of human Fas as an antigen.
- a monoclonal antibody HFE7A which is one of the preferred anti-Fas monoclonal antibodies contained in the pharmaceutical composition of the present invention, is used to immunize a Fas knockout mouse with human Fas, It can be obtained by culturing a hybridoma obtained by fusing spleen cells and mouse myeoma cells. Specifically, the method described below is used. In the production of monoclonal antibodies, at least the following work steps are required. That is,
- the antigens include the extracellular domain of human Fas and the extracellular domain of mouse interleukin 3 receptor (hereinafter referred to as “IL 3R”) [Nishimura, Y. et al. (1995) J. Immunol. 154, 4395-4403]
- Recombinant protein obtained by introducing phFas-AIC2 into monkey-derived cell line COS-1 and expressing it, and partially purifying it. (Hereinafter referred to as “recombinant human Fas”) is effective.
- phFas—AIC2 can be produced by incorporating DNA encoding a fusion protein of human Fas and mouse IL3R into pME18S, an expression vector for animal cells.
- the DNA, vector, host, etc., encoding Fas are not limited to these.
- a transformant obtained by transforming COS-1 cells with phFas-AIC2 was cultured, and human Fas and mouse IL3R produced in the culture supernatant were cultured.
- the recombinant Fas can be partially purified by performing ion-exchange chromatography using a resource Q column (trade name; manufactured by Pharmacia) on the fusion protein of the above.
- Purified Fas present on the cell membrane of a human cell line can also be used as the antigen.
- the primary structure of Fas is known [see Itoh, N., et al. (1991) Cell 66, 233-243], and is shown in SEQ ID NO: 1 in the sequence listing by a method well known to those skilled in the art.
- a peptide comprising an amino acid sequence can be chemically synthesized and used as an antigen.
- the antigen obtained in the step (a) is mixed with an adjuvant such as Freund's complete or incomplete adjuvant or Limyoioban, and the animal is immunized as an immunogen.
- an adjuvant such as Freund's complete or incomplete adjuvant or Limyoioban
- Fas knockout mice are most preferably used as experimental animals, and such mice are described in Senju, S., et al (1996) International Immunology 8, 423). Can be created.
- the method of immunogen administration for mouse immunization may be any of subcutaneous injection, intraperitoneal injection, intravenous injection, intradermal injection, and intramuscular injection, but subcutaneous injection or intraperitoneal injection is preferred. Immunization can be performed once or several times at appropriate intervals (preferably at intervals of 1 to 5 weeks).
- the antibody titer against the antigen in the serum of the immunized animal is measured, and the effect of the subsequent operations can be enhanced by using the animal having a sufficiently high antibody titer as a source of antibody-producing cells.
- the antibody titers used here include radioisotope immunoassay (hereinafter referred to as "RIA”), solid-phase enzyme immunoassay (hereinafter referred to as "ELISA”), There are various known techniques such as a fluorescent antibody method and a passive hemagglutination method, but the RIA method or the ELISA method is more preferable from the viewpoints of detection sensitivity, speed, accuracy, and possibility of automation of the operation. .
- the measurement of the antibody titer in the present invention can be performed, for example, by the following procedure according to the ELISA method.
- the purified or partially purified Fas is adsorbed on a solid phase surface such as a 96-well plate for ELISA, and the solid phase surface on which the antigen is not adsorbed is exposed to a protein unrelated to the antigen, for example, a serum albumin (hereinafter referred to as “serum albumin”).
- serum albumin a serum albumin
- the sample is contacted with a serially diluted sample (eg, mouse serum) as the first antibody, and the anti-Fas antibody in the sample is bound to the antigen.
- an antibody against a mouse antibody labeled with an enzyme is added as a second antibody to bind to the mouse antibody.
- a substrate of the enzyme is added, and a change in absorbance due to color development based on the decomposition of the substrate is measured, thereby obtaining an antibody titer. Is calculated.
- a cell line generally obtained from a mouse for example, an 8-azaguanine-resistant mouse (derived from BAL Bc) myeloma strain P3X63Ag8U.1 (P3-Ul) [Yelton, DE et al. Current Topics in Microbiology and Immunology, 81, 1-7 (1978)], P3 / NSI 1-Ag4_l (NS-1) [Kohler, G. et al. European J. Imrau nology, 6, 511-519 (1976) )], Sp2 / 0-Agl4 (SP-2) [Shulman, M. et al. Nature, 276, 269-270 (1978)], P3X63Ag8.653 (653) [Kearney, JF et al.
- Antibody-producing cells are plasma cells and lymphocytes which are precursor cells thereof, which may be obtained from any part of an individual, such as spleen, lymph node, peripheral blood, or a combination thereof as appropriate. Splenocytes are most commonly used. After the final immunization, a site where antibody-producing cells are present, for example, a spleen is removed from a mouse having a predetermined antibody titer, and spleen cells as antibody-producing cells are prepared.
- One of the most commonly used methods for spleen cells and the _ myelo obtained in the process ⁇ -fusion-fusion-hand-step- is that the cytotoxicity is relatively low. This is a method that uses polyethylene glycol, which is a small and easy fusion operation.
- This method includes, for example, the following procedure. Wash the spleen cells and myeloma well with a serum-free medium (for example, RPMI 1640) or phosphate-buffered saline (PBS) to determine the number of spleen cells and myeloma cells. Mix so that the ratio is about 5: 1 to 10: 1, and centrifuge. Remove the supernatant, loosen the sedimented cells, and stir with a serum-free medium containing 1 ml of 50% (w / v) polyethylene glycol (molecular weight 1000-4000). Is dropped. Then, slowly add 10 ml of serum-free medium and centrifuge.
- a serum-free medium for example, RPMI 1640
- PBS phosphate-buffered saline
- IL-12 normal medium
- HATJ hypoxanthine / aminopterin 'thymidine
- IL-12 mouse interleukin_2
- myeoma cells are 8-azaguanine resistant strains, ie, hypoxanthine 'guanine' phosphoribosyltransferase (HG PRT) deficiency
- HG PRT hypoxanthine 'guanine' phosphoribosyltransferase
- the unfused myeloma cells and the fused cells of myeloma cells cannot survive in a HAT-containing medium.
- a fused cell of antibody-producing cells or a hybridoma of an antibody-producing cell and a myeloma cell can survive, but a fused cell of antibody-producing cells has a life span.
- the hybridomas of the antibody-producing cells and the myeloma cells survive, and as a result, the hybridomas can be selected.
- the medium is replaced with a medium in which aminopterin has been removed from the HAT medium (hereinafter referred to as “HT medium”). Thereafter, a part of the culture supernatant is collected, and the anti-Fas antibody titer is measured, for example, by ELISA.
- the above fusion protein when used as an antigen for ELISA, it is necessary to remove the clone so as not to select a clone that produces an antibody that specifically binds to the extracellular region of mouse IL3 receptor. It is. The presence or absence of such a clone can be confirmed, for example, by ELISA using the mouse IL3 receptor or its extracellular region as an antigen.
- the method using an 8-azaguanine-resistant cell line has been described above, but other cell lines can also be used according to the selection method of the hybridoma, and in that case, the composition of the medium used also changes.
- the antibody titer is measured in the same manner as described in step (b), and the hybridoma that has been found to produce a specific antibody is transferred to another plate and cloned.
- the cloning method includes a limiting dilution method in which a plate is diluted to contain one hybridoma per well, a soft agar method in which the colony is collected by culturing in a soft agar medium, and a micromanipulator. A method of removing and culturing individual cells, separating one cell with a cell sorter
- the limiting dilution method is simple and often used. For a well with an antibody titer, for example, repeat the limiting dilution method 2 to 4 times, and select a stable antibody titer as an anti-Fas monoclonal antibody-producing hybridoma strain. . Furthermore, anti-Fas monoclonal antibody-producing cells are obtained by selecting a hybridoma that produces an antibody that binds to mouse Fas in the same manner.
- the mouse Fas used at this time includes, for example, a DNA expression plasmid vector pME1 which encodes a fusion protein of a mouse Fas extracellular region and a mouse IL3 receptor extracellular region. 8 S—mF as—AIC [see Nishimura, Y.
- mouse-mouse hybridoma HF E7A which is a cell producing an anti-Fas monoclonal antibody suitable as an active ingredient to be contained in the pharmaceutical composition of the present invention, is 1-3-1, Tsukuba East, Ibaraki, Japan. It has been deposited internationally with the Institute of Biotechnology, the National Institute of Advanced Industrial Science and Technology on February 20, 1999, and has the accession number FERM BP-5828. Therefore, for example, when preparing an antibody using mouse-mouse hybridoma HFE7A, the antibody can be prepared from step (g) described below, omitting steps ( ⁇ ).
- Hybridomas that have been cloned are cultured by replacing the medium with HT medium and normal medium.
- Large-scale cultivation is performed by rotary culture using large culture bottles or spinner culture.
- an anti-Fas monoclonal antibody which the preventive or therapeutic agent of the present invention contains as an active ingredient can be obtained.
- the anti-prophylactic or therapeutic agent of the present invention can be used as an active ingredient.
- Fas monoclonal antibody Ascites containing a large amount of the Fas monoclonal antibody can be obtained.
- a commercially available monoclonal antibody purification kit for example, M Ab Drap GII kit; manufactured by Pharmacia
- the monoclonal antibody thus obtained has high antigen specificity for human and mouse Fas.
- the identification method includes the Ouchterlony method, the ELISA method, and the RIA method.
- the Oktoterloni method is simple but requires concentration if the concentration of monoclonal antibody is low.
- the ELISA method or the RIA method is used, the culture supernatant is reacted with the antigen-adsorbed solid phase as it is, and antibodies corresponding to various immunoglobulin isotypes and subclasses are used as secondary antibodies. It is possible to identify the isotype and subclass of the monoclonal antibody.
- a commercially available identification kit eg, Mouse Typer Kit; manufactured by Bio-Rad
- a DNA encoding a heavy or light chain of an anti-Fas monoclonal antibody suitable as an active ingredient to be contained in the pharmaceutical composition of the present invention was prepared using a hybrid that produces the anti-Fas monoclonal antibody.
- RNA can be obtained by preparing mRNA from doma cells, converting the mRNA into cDNA by reverse transcriptase, and isolating the DNA encoding the heavy chain or light chain of the antibody.
- the guanidine-thiosineto-cesium chloride method which can employ the guanidine-thiosineto-hot-phenol method or the guanidine-thiosine-to-guanidine-hydrochloric acid method, is preferred.
- To prepare mRNA from cells first prepare total RNA, and then use oligo (dT) cellulose from the total RNA.
- RNA + RNA such as oligo (dT) latex beads or a method of directly purifying from a cell lysate using the carrier.
- the method for preparing total RNA include alkaline sucrose density gradient centrifugation [see Dougherty, WG and Hiebert, E. (1980) Viology 101, 466-474], guanidine thiosinate phenol method, guanidine The thiocyanate trifluoresceinium method, the phenol.SDS method and the like can also be adopted, but the method using guanidine thiocyanate and cesium chloride [Chirgwin, JM, et al. (1979) Biochemistry 18, 5294-5299] is available.
- RNA obtained as described above as type III a single-stranded cDNA is synthesized by a reverse transcriptase reaction, and then a double-stranded cDNA is synthesized from the single-stranded cDNA.
- this method include the S1 nuclease method [Efstratiadis, A., et al. (1976) Cell 7, 279-288], the Gubler-Hoffman method [Gubler, U. and Hoffman, BJ (1983) Gene 25 , 263-269], Okayama-Berg method
- PCR Polymerase chain reaction
- the double-stranded cDNA obtained in this manner is incorporated into a cloning vector, and the obtained recombinant vector is introduced into a microorganism such as Escherichia coli and transformed, and tetracycline resistance or ampicillin resistance is used as an indicator. As a result, a transformant can be selected. Transformation of Escherichia coli is performed by the Hanahan method [see Hanahan, D. (1983) J. Mol. Biol. 166, 557-580], that is, by using a recombinant cell prepared in the presence of calcium chloride, magnesium chloride or rubidium chloride.
- the method can be carried out by adding the recombinant DNA vector.
- a plasmid as a vector, it is necessary to have the above-mentioned drug resistance gene. It is also possible to use a cloning vector other than plasmid, for example, a lambda-based phage.
- a method for selecting a strain having cDNA encoding each subject of the desired anti-human Fas antibody from the transformants obtained as described above for example, the following various methods can be adopted.
- these operations can be omitted.
- sense-strand and antisense-strand oligonucleotide primers corresponding to a part of the amino acid sequence are synthesized, and these are combined. Perform a polymerase chain reaction [see Saiki, RK, et al. (1988) Science 239, 487-49] to amplify a DNA fragment encoding the desired anti-human Fas antibody heavy or light chain subunit. You.
- the type I DNA used here was synthesized by reverse transcriptase reaction from mRNA of a hybridoma (FERM BP-58828) producing anti-human Fas monoclonal antibody HFE7A. cDNA can be used.
- the DNA fragment prepared in this manner can be directly incorporated into a plasmid vector using a commercially available kit or the like, or the fragment is labeled with 32 P, 35 S, or biotin, and this is used as a probe.
- the desired clone can also be selected by performing colony hybridization or plaque hybridization using the clone.
- a monoclonal antibody HFE7A suitable as an active ingredient to be contained in the pharmaceutical composition of the present invention is an immunoglobulin G1 (hereinafter referred to as "IgG1") molecule, and a heavy chain ( y 1 chain) and light chain ( ⁇ chain).
- each subunit is isolated using a well-known method such as electrophoresis or column chromatography, and then an automated protein sequencer (for example, Shimadzu Corporation) is used. It is preferable to use a method such as PPSQ-10) manufactured by Seisakusho Co., Ltd. to analyze the N-terminal amino acid sequence of each subunit. From the target transformant obtained as described above, a method for collecting cDNA encoding each of the subunits of the anti-human Fas monoclonal antibody protein can be obtained by a known method LManiatis, T., et al. et al.
- the amino acid sequence of the target protein corresponds to the amino acid sequence.
- a nucleotide sequence estimated from the codon usage or a plurality of nucleotide sequences combining possible nucleotide sequences can be used. In the latter case, inosine is used.
- this pro one blanking I2 P, 35 S or as labeling with such Biochin
- nitrocellulose filters one and Haiburidizu obtained by modifying fix the DNA of transformants And the resulting positive strains are selected.
- the determination of the sequence of the DNA obtained in this way can be carried out, for example, by the chemical modification method of Maxamuir Gilbert [see Maxam, AM and Gilbert, W. (1980) in “Methods in Enzymology” 65, 499-576]. It can be carried out by a xynucleotide chain termination method [see Messing, J. and Vieira, J. (1982) Gene 19, 269-276] and the like.
- an automatic base sequence determination system using a fluorescent dye has become widespread (for example, a sequence robot "CATALYST 800" manufactured by PerkinElmer Japan Co., Ltd. and a model 373ADNA sequencer).
- a sequence robot "CATALYST 800" manufactured by PerkinElmer Japan Co., Ltd. and a model 373ADNA sequencer By using such a system, DNA nucleotide sequencing can be performed efficiently and safely.
- the nucleotide sequences of the DNA of the present invention thus determined, and the N-terminal amino acid sequence data of each of the heavy and light chains
- the amino acid sequences of the entire heavy and light chains of the monoclonal antibody of the present invention can be determined from the data.
- the cassette mutation method [Toshimitsu Kishimoto, "Natural Chemistry Laboratory 2 Nucleic Acid III Recombinant DNA Technology” 242 -251].
- Such various DNAs are produced by chemical synthesis of nucleic acids according to a conventional method such as the phosphite triester method [see Hunkapiller, M., et al. (1984) Nature 310, 105-111].
- the codon for the desired amino acid is known per se and may be selected arbitrarily. For example, the codon for the desired amino acid may be determined according to a conventional method in consideration of the frequency of codon usage of the host used.
- Partial modification of these nucleotide sequence codons can be performed by a site-directed mutagenesis method (site-specific mutagenesis) using a primer comprising a synthetic oligonucleotide encoding the desired modification according to a conventional method. Natl. Acad. Sci. USA 81, 5662-5666], DF, et al. (1984). Whether or not a certain DNA hybridizes with DNA encoding the heavy or light chain of an anti-Fas monoclonal antibody suitable as an active ingredient to be contained in the pharmaceutical composition of the present invention is determined by, for example, The DNA is used for the random primer method [Feinberg, AP and Vogelstein, B. (1983) Anal, biochem.
- probe DNA labeled with [a-- :, P] dCTP etc. It can be determined by conducting experiments. First, the DNA to be examined is adsorbed on, for example, a nitrocellulose membrane or a Niopen membrane, and if necessary, treated with alkali modification or the like, and then solidified by heating or ultraviolet rays.
- This membrane is treated with 6 XSSC (1 XSSC is 0.15 M sodium chloride, 0.015 M trisodium citrate solution) and 5% Denhardt's
- 6 XSSC 1 XSSC is 0.15 M sodium chloride, 0.015 M trisodium citrate solution
- SDS sodium dodecyl sulfate
- the heavy chain or light chain of an anti-Fas monoclonal antibody suitable as an active ingredient to be included in the pharmaceutical composition of the present invention can be obtained from any cDNA library or genomic library.
- DNA that hybridizes with the DNA to be isolated [see Maniatis, T., et al. (1982) in "Molecular Cloning A laboratory Manual Cold Spring Harbor Laboratory, NY.”] 0
- the obtained DNAs By incorporating each of the obtained DNAs into an expression vector, it is possible to introduce them into prokaryotic or eukaryotic host cells, and to express each gene in those host cells. Examples of the host include Escherichia coli, Bacillus subtilis, etc.
- a replicator derived from a species compatible with the host is required.
- the host cell may be transformed with a plasmid, which contains a plasmid, such as a replication origin and a promoter sequence such as lac UV5, etc.
- the vector imparts selectivity due to the phenotypic trait in the transformed cell.
- Escherichia coli JM109 strain derived from E. coli K12 strain or the like is often used, and as a vector, pBR322 or a pUC-based plasmid is generally used. It is often used, but is not limited to these, and any of various known strains and vectors can be used ..
- tryptophan (trp) promoter In Escherichia coli, tryptophan (trp) promoter, lactose (Lac) promoter, tryptophan 'lactose (tac) promoter, lipoprotein (lpp) promoter, bacteriophage-derived ram Da ( ⁇ ) PL promoter, polypeptide chain elongation factor Tu (tufB) promoter And the like, but are not limited to these.
- the Bacillus subtilis for example, the 207-25 strain is preferable, and as the vector, pTUB228 (see Ohmura, K., et al. (1984) J. Biochem. 95, 87-93) or the like is used. But not limited to this.
- Eukaryotic host cells include cells such as vertebrates and yeast. Examples of vertebrate cells include COS-1, a monkey-derived cell line [Gluzman, Y. (1981) Cel l 23 , 175-182].
- yeast baker's yeast (Saccharomyces cerevisiae), alcohol-assimilating yeast (Pi chia pastori s), fission yeast (Schizos saccharomyces pombe) and the like are used.
- the cells exemplified here are generally used as host cells.
- the force is not limited to these.
- a vertebrate cell expression vector a vector having a promoter, an RNA splicing site, a polyadenylation site, a transcription termination sequence, etc. which is usually located upstream of the gene to be expressed can be used. Further, if necessary, it may have a replication origin.
- An example of such an expression vector is p SV 2 dhfr having an early promoter of SV 40 [see Subramani, S., et al. (1981) Mol. Cell. Bio. 1, 854-864]. It can be exemplified, but not limited to this.
- yeast expression vectors include the alcohol dehydrogenase gene promoter [see Bennetzen, J. Shi and Hall, BD (1982) J. Biol. Chem. 257, 3018-3025] and And a promoter of a galactose metabolizing enzyme gene (eg, gal10) [see Ichikawa, K., et al. (1993) Biosci. Biotech. Biochem. 57, 1686-1690] and the like.
- the expression vector when COS-1 is used as a host cell, the expression vector has an SV40 origin of replication, is capable of autonomous growth in C ⁇ S-1, and furthermore has a transcription promoter.
- An expression vector with a transcription termination signal, and an RNA splice site can be used.
- the expression vector is obtained by the DEAE-dextran method [see Luthman, H. and agnusson, G. (1983) Nucleic Acids Res. 11, 1295-1308], the calcium phosphate-DNA coprecipitation method [Graham, F. And van der Eb, AJ (1973) Virology 52, 456-457] and electroporation [Neumann, E., et al. (1982) EMBO J.
- the desired transformed cells can be obtained.
- co-transforming COS-1 with an expression vector comprising DNA encoding the heavy chain and an expression vector comprising DNA encoding the same light chain these DNAs are obtained.
- the method for producing a recombinant anti-Fas antibody is not limited to the above.For example, it is possible to retain both DNAs encoding heavy and light chains and express them simultaneously.
- a method of constructing a single expression vector and transforming COS-1 cells with the vector can also be used.
- the desired transformant obtained above can be cultured according to a method well known to those skilled in the art, and the culture produces a recombinant anti-Fas antibody inside or outside the transformant cells.
- the medium used for the culture can be appropriately selected from various types commonly used depending on the host cell used. For example, in the case of COS-1, the RPMI 1640 medium or the Dulbecco's modified Eagle medium A medium such as (DMEM) to which serum components such as fetal calf serum (FCS) are added as necessary can be used.
- the culture temperature at the time of culturing the transformant may be any temperature as long as it does not significantly lower the protein synthesis ability in cells, but is preferably 32 to 42 ° C, most preferably 37 to 42 ° C.
- the fraction containing the anti-Fas antibody protein which is produced intracellularly or extracellularly in the transformant as described above, can be obtained by various known protein separation procedures using the physical properties and chemical properties of the protein. Can be separated and purified. Examples of such a method include, for example, treatment with a normal protein precipitant, ultrafiltration, molecular sieve chromatography (gel filtration), adsorption chromatography, ion exchange chromatography, affinity chromatography, and high-speed chromatography. Various types of chromatography, such as liquid chromatography (HPLC), dialysis, and combinations thereof can be used.
- HPLC liquid chromatography
- a recombinant anti-Fas antibody can be easily produced with high yield and high purity.
- the same ELISA method as in the case of evaluating the antibody titer at the time of mouse immunization is preferable. It is.
- compounds having folate antagonism or dihydrofolate reductase inhibitory activity for example, the compounds represented by the above formulas (I) to (XIX) can be obtained according to the description in the literature referred to in the description of each compound. Can be.
- the pharmaceutical composition of the present invention can be used as a prophylactic or therapeutic agent for an autoimmune disease or rheumatoid arthritis patient as an active ingredient.
- a prophylactic or therapeutic agent can be administered in various forms, such as tablets, capsules, granules, powders, syrups, etc., or injections, drops, Parenteral administration by suppositories and the like can be mentioned.
- the dose of the anti-human Fas antibody and the compound having folate antagonism or dihydrofolate reductase inhibitory activity in the pharmaceutical composition of the present invention varies depending on the respective antibody used and the strength of the action specific to the compound.
- the pharmaceutical composition of the present invention is preferably prepared as a solution containing 0.1 to 100 ng / m1 of CH11 or HFE7A and 0.05 to 5 nM of methotrexate. Not limited to a range.
- the dose varies depending on symptoms, age, body weight, etc., but usually 0.1 mg to 100 mg of anti-human Fas antibody is administered by subcutaneous injection, intramuscular injection or intravenous injection at a time. can do.
- the efficacy of the pharmaceutical composition of the present invention prepared as described above in the treatment of an autoimmune disease or rheumatoid arthritis can be measured by using cells (for example, human lymphocyte cells) in a medium supplemented with the pharmaceutical composition of the present invention.
- Strain HPB— ALL see Morikawa, S., et al. (1978) Int. J. Cancer 21, 166-170
- Jurkat American Type Culture No.
- TIB-152 derived from rheumatoid arthritis patients Synovial cells, etc.
- the survival rate is determined by MTT assay (see Green, M., et al. (1984) J. Immunological Methods 70, 257-268) and XTT described in the Examples below.
- the pharmaceutical composition of the present invention can be confirmed by measuring with an Atzey method or the like: abnormally proliferating in autoreactive lymphocytes, which is one of the main causes of autoimmune diseases, and in the affected area of rheumatoid arthritis.
- Dose of anti-Fas for synovial cells Since capable of inducing apoptosis in the body, their effective in the treatment of autoimmune diseases or chronic Takashi Seki Riumachi.
- FIG. 1 is a diagram showing a synergistic effect of an anti-human Fass monoclonal antibody CH11 and methotrexate on the induction of cell apoptosis.
- FIG. 2 is a diagram showing a synergistic effect of the anti-Hutus Monoclonal monoclonal antibody HFE7A and methotrexate on the induction of cell apoptosis.
- FIG. 3 is a graph showing cell viability in the presence of turaxate.
- Example 1 Example 1
- an anti-human Fas monoclonal antibody HFE7A or CHI1 (manufactured by Institute of Medical Biology, Inc.) described in European Patent Publication No. 0099816 was used.
- RPM containing the human lymphocyte cell line HPB—ALL (see Morikawa, S., et al. (1978) Int. J. Cancer 21, 166-170) with 10% FCS (manufactured by Gibco BRL) Culture for 3 days at 37 ° C, 5% CO2 in I164 medium.
- a represents the measured value of the test well
- b represents the measured value of the cell-free well
- c represents the measured value of the well containing no antibody.
- the prophylactic or therapeutic agent of the present invention comprises an anti-human Fas antibody and a compound having folate antagonism or dihydrofolate reductase inhibitory activity which are pharmacologically acceptable in water or other water. It is ready for use as an ampoule of a sterile solution or suspension dissolved in a possible solution. Specifically, for example, 0.5 mg of anti-human Fas antibody and a final amount of 0.05 nM methotrexate are dissolved in 1 liter of water for injection, and aseptically. Dispense into ampules and seal.
- a sterile powder preparation (preferably freeze-dried anti-human Fas antibody and a compound having folate antagonism or dihydrofolate reductase inhibitory action) is filled in an ampoule, and pharmacology is used at the time of use. It may be diluted with an acceptable solution.
- the present invention provides a novel pharmaceutical composition useful as an agent for preventing or treating autoimmune diseases and rheumatoid arthritis.
- the amount of the anti-Fas antibody used can be reduced by using a compound having a folate-antagonizing action or a dihydrofolate reductase-inhibiting action in combination with the anti-Fast-Fas antibody.
- the pharmaceutical composition of the present invention can be used for an excellent autoimmune disease or chronic disease capable of withstanding long-term administration. It is useful as an agent for preventing or treating rheumatoid arthritis.
Description
Claims
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR0010909-6A BR0010909A (pt) | 1999-05-24 | 2000-05-24 | Composição farmacêutica, agente que tem atividade indutora de apoptose, e, uso de um anticorpo fas anti-humano |
EP00931546A EP1180369A4 (en) | 1999-05-24 | 2000-05-24 | ANTI-FAS ANTIBODY MEDICAL COMPOSITIONS |
PL00352159A PL352159A1 (en) | 1999-05-24 | 2000-05-24 | Pharmaceutical compositions containing antibody against the fas |
KR1020017015062A KR20020008197A (ko) | 1999-05-24 | 2000-05-24 | 항-Fas 항체를 함유하는 의약 조성물 |
CA002373992A CA2373992A1 (en) | 1999-05-24 | 2000-05-24 | Medicinal compositions containing anti-fas antibody |
NZ515598A NZ515598A (en) | 1999-05-24 | 2000-05-24 | Synergistic medicinal compositions containing anti-Fas antibody and a compound having a folate antagonistic activity or a dihydrofolate reductase inhibiting activity |
MXPA01012206A MXPA01012206A (es) | 1999-05-24 | 2000-05-24 | Composiciones farmaceuticas que contienen anticuerpo anti-fas. |
AU49486/00A AU761544C (en) | 1999-05-24 | 2000-05-24 | Medicinal compositions containing anti-Fas antibody |
IL14656600A IL146566A0 (en) | 1999-05-24 | 2000-05-24 | A pharmaceutical composition containing anti-fas antibody |
US09/989,620 US6746673B2 (en) | 1999-05-24 | 2001-11-20 | Pharmaceutical compositions containing anti-Fas antibody |
NO20015711A NO20015711L (no) | 1999-05-24 | 2001-11-23 | Farmasöytiske preparater inneholdende anti-Fas-antistoff |
HK02103876.1A HK1042049A1 (zh) | 1999-05-24 | 2002-05-23 | 含有抗fas抗體的醫療組合物 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP14303399 | 1999-05-24 | ||
JP11/143033 | 1999-05-24 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/989,620 Continuation-In-Part US6746673B2 (en) | 1999-05-24 | 2001-11-20 | Pharmaceutical compositions containing anti-Fas antibody |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000071160A1 true WO2000071160A1 (fr) | 2000-11-30 |
Family
ID=15329357
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2000/003324 WO2000071160A1 (fr) | 1999-05-24 | 2000-05-24 | Compositions medicinales contenant un anticorps anti-fas |
Country Status (19)
Country | Link |
---|---|
US (1) | US6746673B2 (ja) |
EP (1) | EP1180369A4 (ja) |
KR (1) | KR20020008197A (ja) |
CN (1) | CN1191861C (ja) |
AU (1) | AU761544C (ja) |
BR (1) | BR0010909A (ja) |
CA (1) | CA2373992A1 (ja) |
CZ (1) | CZ20014181A3 (ja) |
HK (1) | HK1042049A1 (ja) |
HU (1) | HUP0201333A3 (ja) |
IL (1) | IL146566A0 (ja) |
MX (1) | MXPA01012206A (ja) |
NO (1) | NO20015711L (ja) |
NZ (1) | NZ515598A (ja) |
PL (1) | PL352159A1 (ja) |
RU (1) | RU2222347C2 (ja) |
TR (1) | TR200103396T2 (ja) |
WO (1) | WO2000071160A1 (ja) |
ZA (1) | ZA200109575B (ja) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003020768A1 (en) * | 2001-08-28 | 2003-03-13 | Sankyo Company, Limited | A method for the treatment or prevention of bone erosion |
WO2003004049A3 (en) * | 2001-07-02 | 2003-04-24 | Ice Biolog Ltd | Use of polyclonal anti-hiv goat serum as a therapeutic agent |
WO2003064472A2 (en) * | 2002-01-28 | 2003-08-07 | Aimsco Limited | Treatment of ms with goat serum |
WO2003103710A1 (ja) * | 2002-06-07 | 2003-12-18 | 三共株式会社 | 骨破壊の治療または予防剤組成物の併用効果 |
EA014287B1 (ru) * | 2002-01-28 | 2010-10-29 | Эймско Лимитед | Способ лечения заболевания двигательных нейронов козьей сывороткой |
WO2010149786A1 (en) * | 2009-06-26 | 2010-12-29 | Deutsches Krebsforschungszentrum | Pyrido [2, 3-d] pyrimidines as wnt antagonists for treatment of cancer and arthritis |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1087993T3 (da) | 1998-06-18 | 2008-07-14 | Imed Ab | Fas-peptider og antistoffer til at modulere apoptose |
US6989386B2 (en) * | 2002-04-30 | 2006-01-24 | Dana-Farber Cancer Institute | Pharmaceutically active ornithine derivatives, ammonium salts thereof and methods of making same |
US20050032807A1 (en) * | 2003-08-06 | 2005-02-10 | Rosenwald Lindsay A. | Methods of treating inflammatory diseases with ammonium salts of ornitihine derivatives |
GB0427568D0 (en) * | 2004-12-16 | 2005-01-19 | Resolution Chemicals Ltd | Particle-size reduction apparatus, and the use thereof |
US8052971B2 (en) * | 2005-11-21 | 2011-11-08 | MG Biologics | Oral use of specific antibodies for intestinal health |
CN101092417B (zh) * | 2006-06-19 | 2011-04-27 | 上海金色医药科技发展有限公司 | 一种叶酸类似物及用于医疗的叶酸类似物的盐 |
JP5603775B2 (ja) | 2007-10-08 | 2014-10-08 | エムエムヴィ メディスィンズ フォー マラリア ヴェンチュアー | 柔軟な側鎖を有する抗マラリア化合物 |
PL2310970T3 (pl) | 2008-06-20 | 2013-10-31 | Novartis Ag | Metody identyfikacji w białkach regionów wiązania makrocząsteczek i regionów podatności na agregację i zastosowanie tych metod |
EP2310412B1 (en) | 2008-06-20 | 2018-02-21 | Novartis AG | Immunoglobulins with reduced aggregation |
CN105169389A (zh) * | 2008-08-01 | 2015-12-23 | 阿克西斯股份有限公司 | 骨关节炎治疗剂及预防剂 |
KR20180056805A (ko) * | 2009-06-04 | 2018-05-29 | 노파르티스 아게 | IgG 콘쥬게이션을 위한 자리의 확인 방법 |
KR101138460B1 (ko) | 2009-10-12 | 2012-04-26 | 한국생명공학연구원 | 항-fasn 자가면역 항체를 포함하는 간암 진단 마커 및 이의 항원을 포함하는 간암 진단용 조성물 |
WO2011046309A2 (en) * | 2009-10-12 | 2011-04-21 | Korea Research Institute Of Bioscience And Biotechnology | A diagnostic marker for hepatocellular carcinoma comprising anti-fasn autoantibodies and a diagnostic composition for hepatocellular carcinoma comprising antigens thereof |
US10431325B2 (en) | 2012-08-03 | 2019-10-01 | Novartis Ag | Methods to identify amino acid residues involved in macromolecular binding and uses therefor |
Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0021292A1 (en) * | 1979-06-14 | 1981-01-07 | The Wellcome Foundation Limited | Alkoxybenzylpyridopyrimidines, methods for their preparation and pharmaceutical formulations thereof |
WO1986005181A1 (en) * | 1985-03-08 | 1986-09-12 | The Trustees Of Princeton University | PYRIDO AD2,3-d BDPYRIMIDIN DERIVATIVES |
EP0334636A2 (en) * | 1988-03-24 | 1989-09-27 | Takeda Chemical Industries, Ltd. | Pyrrolopyrimidine derivatives, their production and use |
US4912112A (en) * | 1986-02-06 | 1990-03-27 | Saarstickstoff-Fatol Gmbh Chem.-Pharm. Fabrik | Substituted 2,4-diamino-5-benzylpyrimidines, their preparation and their use as medicaments with an antimicrobial activity |
WO1991010666A1 (en) * | 1990-01-18 | 1991-07-25 | Nair Madhavan G | Three new non-polyglutamatable deazaaminopterins and process for preparing the same |
WO1992008461A1 (en) * | 1990-11-14 | 1992-05-29 | Protos Corporation | Specific inhibition of dihydrofolate reductase and compounds therefor |
WO1993013079A1 (en) * | 1991-12-20 | 1993-07-08 | Agouron Pharmaceuticals, Inc. | Antifolate quinazolines |
WO1995009845A1 (en) * | 1993-10-06 | 1995-04-13 | Eli Lilly And Company | Pyrimidinyl-glutamic acid derivatives |
EP0709097A1 (en) * | 1994-09-27 | 1996-05-01 | Santen Pharmaceutical Co., Ltd. | Anti-Fas antibody for rheumatic disease |
EP0866131A2 (en) * | 1997-03-21 | 1998-09-23 | Sankyo Company Limited | Humanized anti-human fas antibody |
EP0897724A1 (en) * | 1996-03-19 | 1999-02-24 | Chugai Seiyaku Kabushiki Kaisha | Uveitis remedy |
EP0909816A1 (en) * | 1997-04-01 | 1999-04-21 | Sankyo Company Limited | Anti-fas antibodies |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02237935A (ja) | 1989-03-10 | 1990-09-20 | Bio Kagaku Kenkyusho:Kk | エイズ処置剤 |
US5008391A (en) * | 1989-07-07 | 1991-04-16 | Eli Lilly And Company | Enantioselective synthesis of antifolates |
WO1991010448A1 (en) | 1990-01-19 | 1991-07-25 | German Cancer Research Center | A cell surface antigen associated with cellular apoptosis |
JP2963535B2 (ja) | 1990-01-19 | 1999-10-18 | ジヤーマン・キヤンサー・リサーチ・センター | Htlv−1ウイルス感染細胞の増殖阻害用組成物 |
US5877176A (en) * | 1991-12-26 | 1999-03-02 | Cornell Research Foundation, Inc. | Blocking induction of tetrahydrobiopterin to block induction of nitric oxide synthesis |
WO1996022303A1 (en) * | 1995-01-16 | 1996-07-25 | Commonwealth Scientific And Industrial Research Organisation | Therapeutic compound - fatty acid conjugates |
US6221615B1 (en) * | 1995-05-12 | 2001-04-24 | Apoptosis Technology, Inc. | Peptides and compositions which modulate apoptosis |
CA2230852A1 (en) * | 1995-08-30 | 1997-03-06 | The Regents Of The University Of California | Therapy for cellular accumulation in chronic inflammatory diseases |
US6544523B1 (en) * | 1996-11-13 | 2003-04-08 | Chiron Corporation | Mutant forms of Fas ligand and uses thereof |
US6001962A (en) * | 1996-11-15 | 1999-12-14 | The Regents Of The University Of California | Modified Fas ligands |
US6098631A (en) * | 1998-01-21 | 2000-08-08 | The Regents Of The University Of Michigan | Compositions and methods for treating autoimmune disease |
-
2000
- 2000-05-24 AU AU49486/00A patent/AU761544C/en not_active Ceased
- 2000-05-24 HU HU0201333A patent/HUP0201333A3/hu unknown
- 2000-05-24 CA CA002373992A patent/CA2373992A1/en not_active Abandoned
- 2000-05-24 TR TR2001/03396T patent/TR200103396T2/xx unknown
- 2000-05-24 CN CNB008107807A patent/CN1191861C/zh not_active Expired - Fee Related
- 2000-05-24 RU RU2001131725/15A patent/RU2222347C2/ru not_active IP Right Cessation
- 2000-05-24 BR BR0010909-6A patent/BR0010909A/pt not_active IP Right Cessation
- 2000-05-24 NZ NZ515598A patent/NZ515598A/en unknown
- 2000-05-24 KR KR1020017015062A patent/KR20020008197A/ko not_active Application Discontinuation
- 2000-05-24 EP EP00931546A patent/EP1180369A4/en not_active Withdrawn
- 2000-05-24 WO PCT/JP2000/003324 patent/WO2000071160A1/ja not_active Application Discontinuation
- 2000-05-24 IL IL14656600A patent/IL146566A0/xx unknown
- 2000-05-24 MX MXPA01012206A patent/MXPA01012206A/es unknown
- 2000-05-24 CZ CZ20014181A patent/CZ20014181A3/cs unknown
- 2000-05-24 PL PL00352159A patent/PL352159A1/xx not_active Application Discontinuation
-
2001
- 2001-11-20 US US09/989,620 patent/US6746673B2/en not_active Expired - Fee Related
- 2001-11-20 ZA ZA200109575A patent/ZA200109575B/xx unknown
- 2001-11-23 NO NO20015711A patent/NO20015711L/no not_active Application Discontinuation
-
2002
- 2002-05-23 HK HK02103876.1A patent/HK1042049A1/zh unknown
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0021292A1 (en) * | 1979-06-14 | 1981-01-07 | The Wellcome Foundation Limited | Alkoxybenzylpyridopyrimidines, methods for their preparation and pharmaceutical formulations thereof |
WO1986005181A1 (en) * | 1985-03-08 | 1986-09-12 | The Trustees Of Princeton University | PYRIDO AD2,3-d BDPYRIMIDIN DERIVATIVES |
US4912112A (en) * | 1986-02-06 | 1990-03-27 | Saarstickstoff-Fatol Gmbh Chem.-Pharm. Fabrik | Substituted 2,4-diamino-5-benzylpyrimidines, their preparation and their use as medicaments with an antimicrobial activity |
EP0334636A2 (en) * | 1988-03-24 | 1989-09-27 | Takeda Chemical Industries, Ltd. | Pyrrolopyrimidine derivatives, their production and use |
WO1991010666A1 (en) * | 1990-01-18 | 1991-07-25 | Nair Madhavan G | Three new non-polyglutamatable deazaaminopterins and process for preparing the same |
WO1992008461A1 (en) * | 1990-11-14 | 1992-05-29 | Protos Corporation | Specific inhibition of dihydrofolate reductase and compounds therefor |
WO1993013079A1 (en) * | 1991-12-20 | 1993-07-08 | Agouron Pharmaceuticals, Inc. | Antifolate quinazolines |
WO1995009845A1 (en) * | 1993-10-06 | 1995-04-13 | Eli Lilly And Company | Pyrimidinyl-glutamic acid derivatives |
EP0709097A1 (en) * | 1994-09-27 | 1996-05-01 | Santen Pharmaceutical Co., Ltd. | Anti-Fas antibody for rheumatic disease |
EP0897724A1 (en) * | 1996-03-19 | 1999-02-24 | Chugai Seiyaku Kabushiki Kaisha | Uveitis remedy |
EP0866131A2 (en) * | 1997-03-21 | 1998-09-23 | Sankyo Company Limited | Humanized anti-human fas antibody |
EP0909816A1 (en) * | 1997-04-01 | 1999-04-21 | Sankyo Company Limited | Anti-fas antibodies |
Non-Patent Citations (20)
Title |
---|
"The Merck Index", 1996, MERCK & CO., INC., WHITEHOUSE STATION NJ, XP002927770 * |
"The merck index", 1996, MERCK & CO., INC., WHITEHOUSE STATION NJ, XP002927771 * |
"The merck index", 1996, MERCK & CO., INC., WHITEHOUSE STATION NJ, XP002927772 * |
FAESSEL,HELENE M. ET AL.: "Super in vitro synergy between inhibitors of dihydrofolate reductase and inhibitors of other folate-requiring enzymes: the critical role of polyglutamylation", CANCER RES., vol. 58, no. 14, 1998, pages 3036 - 3050, XP002927774 * |
FUJISAWA,KOUSHI ET AL.: "Mouse kansetsuen ni taisuru kou Fas kotai no chiryo kouka", MOL. MED., vol. 33, no. 11, 1996, (TOKYO), pages 1254 - 1261, XP002945819 * |
FUJISAWA,KOUSHI ET AL.: "Therapeutic effect of the anti-Fas antibody on arthritis in HTLV-I tax transgenic mice", J. CLIN. INVEST., vol. 98, no. 2, 1996, pages 271 - 278, XP002927779 * |
GENESTIER,LAURENT ET AL.: "Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T cells", J. CLIN. INVEST., vol. 102, no. 2, 1998, pages 322 - 328, XP002927777 * |
HASUNUMA,TOMOKO ET AL.: "Induction of Fas-dependent apoptosis in synovial infiltrating cells in rheumatoid arthritis", INT. IMMUNOL., vol. 8, no. 10, 1996, pages 1595 - 1602, XP002927781 * |
HUGHES,WALTER T. ET AL.: "Anti-pneumocystis carinii activity of PS-15, a new biguanide folate antagonist", ANTIMICROB. AGENTS CHEMOTHER., vol. 37, no. 7, 1993, pages 1417 - 1419, XP002927776 * |
KOTAKE,YOSHIHIKO ET AL.: "Synthesis and antitumor activities of novel 6-5 fused ring heterocycle antifolates: N-(4-(.omega.-)2-amino-4-substituted-6,7-dihydrocyclo penta(d)pyrimidin-5-yl)alkyl)benzoyl)-L-glutamic acids", J. MED. CHEM., vol. 37, no. 11, 1994, pages 1616 - 1624, XP002927773 * |
MCGAHON,ANNE J. ET AL.: "Chemotherapeutic drug-induced apoptosis in human leukaemic cells is independent of the Fas (APO-1/CD95) receptor/ligand system", BR. J. HAEMATOL., vol. 101, no. 3, 1998, pages 539 - 547, XP002927768 * |
MIZUTANI Y. ET AL.: "Sensitization of human bladder cancer cells to fas-mediated cytotoxicity by cis-diaminedichloroplatinum (II)", JOURNAL OF UROLOGY, vol. 160, no. 2, 1998, pages 561 - 570, XP002927767 * |
MIZUTANI,YOUICHI ET AL.: "Doxorubicin sensitizes human bladder carcinoma cells to fas-mediated cytotoxicity", CANCER, vol. 79, no. 6, 1997, (N.Y.), pages 1180 - 1189, XP002927769 * |
MIZUTANI,YOUICHI ET AL.: "Effect of anticancer agents on Fas-mediated cytotoxicity against bladder cancer cells", J. INFECT. CHEMOTHER., vol. 5, no. 3, 1999, pages 139 - 143, XP002927783 * |
NISHIMURA-MORITA,YOSHIKO ET AL.: "Amelioration of systemic autoimmune disease by the stimulation of apoptosis-promoting receptor Fas with anti-Fas mAb", INT. IMMUNOL., vol. 9, no. 12, 1997, pages 1793 - 1799, XP002927778 * |
NOBUTOSHI SERIZAWA: "Atarashii kou fas monoclonal koutai ni yoru chiryoyaku kaihatsu eno kokoromi", SAISHIN IGAKU, vol. 54, no. 4, April 1999 (1999-04-01), pages 917 - 924, XP002945818 * |
ROSOWSKY,ANDRE ET AL.: "Synthesis and biological activity of methotrexate analogs with two acid groups and a hydrophobic aromatic ring in the side chain", J. MED. CHEM., vol. 34, no. 2, 1991, pages 574 - 579, XP002927775 * |
SAKAI,K. ET AL.: "Potential withdrawal of rheumatoid synovium by the induction of apoptosis using a novel in vivo model of rheumatoid arthritis", ARTHRITIS AND RHEUMATISM, vol. 41, no. 7, 1998, pages 1251 - 1257, XP002927780 * |
See also references of EP1180369A4 * |
SUMIDA,TAKAYUKI ET AL.: "Rheumatoid arthritis and apolosis", INTERN. MED., vol. 37, no. 2, 1998, (TOKYO), pages 184 - 188, XP002927782 * |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003004049A3 (en) * | 2001-07-02 | 2003-04-24 | Ice Biolog Ltd | Use of polyclonal anti-hiv goat serum as a therapeutic agent |
CN100423776C (zh) * | 2001-07-02 | 2008-10-08 | 艾姆斯科有限公司 | 多克隆抗-hiv山羊血清作为治疗剂的用途 |
EA013517B1 (ru) * | 2001-07-02 | 2010-06-30 | Эймско Лимитед | Применение козьей сыворотки, полученной иммунизацией козы вич, для изготовления лекарственных средств |
WO2003020768A1 (en) * | 2001-08-28 | 2003-03-13 | Sankyo Company, Limited | A method for the treatment or prevention of bone erosion |
WO2003064472A2 (en) * | 2002-01-28 | 2003-08-07 | Aimsco Limited | Treatment of ms with goat serum |
WO2003064472A3 (en) * | 2002-01-28 | 2003-09-04 | Aimsco Ltd | Treatment of ms with goat serum |
EA014287B1 (ru) * | 2002-01-28 | 2010-10-29 | Эймско Лимитед | Способ лечения заболевания двигательных нейронов козьей сывороткой |
WO2003103710A1 (ja) * | 2002-06-07 | 2003-12-18 | 三共株式会社 | 骨破壊の治療または予防剤組成物の併用効果 |
WO2010149786A1 (en) * | 2009-06-26 | 2010-12-29 | Deutsches Krebsforschungszentrum | Pyrido [2, 3-d] pyrimidines as wnt antagonists for treatment of cancer and arthritis |
EP2266984A1 (en) * | 2009-06-26 | 2010-12-29 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Pyrido[2,3-d]pyrimidines as Wnt antagonists for treatment of cancer and arthritis |
Also Published As
Publication number | Publication date |
---|---|
TR200103396T2 (tr) | 2002-04-22 |
HUP0201333A3 (en) | 2004-11-29 |
AU761544C (en) | 2004-02-12 |
AU761544B2 (en) | 2003-06-05 |
RU2222347C2 (ru) | 2004-01-27 |
CN1191861C (zh) | 2005-03-09 |
NZ515598A (en) | 2004-05-28 |
PL352159A1 (en) | 2003-07-28 |
CZ20014181A3 (cs) | 2002-03-13 |
AU4948600A (en) | 2000-12-12 |
ZA200109575B (en) | 2003-04-30 |
EP1180369A4 (en) | 2002-07-24 |
US6746673B2 (en) | 2004-06-08 |
HUP0201333A2 (en) | 2002-08-28 |
KR20020008197A (ko) | 2002-01-29 |
MXPA01012206A (es) | 2002-06-21 |
CN1364090A (zh) | 2002-08-14 |
NO20015711D0 (no) | 2001-11-23 |
CA2373992A1 (en) | 2000-11-30 |
HK1042049A1 (zh) | 2002-08-02 |
NO20015711L (no) | 2002-01-11 |
IL146566A0 (en) | 2002-07-25 |
EP1180369A1 (en) | 2002-02-20 |
BR0010909A (pt) | 2002-02-19 |
US20020103212A1 (en) | 2002-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2000071160A1 (fr) | Compositions medicinales contenant un anticorps anti-fas | |
US6972323B1 (en) | Anti-Fas antibodies | |
JP4156238B2 (ja) | 腫瘍壊死因子関連アポトーシス誘導性リガンドレセプターについて選択的な抗体、およびそれらの使用 | |
HUE025778T2 (en) | Preparations and methods for the use of therapeutic antibodies | |
BRPI0513078B1 (pt) | ANTICORPO IgG QUE SE LIGA A IL-17 HUMANA E COMPOSIÇÃO LÍQUIDA | |
JP2021509822A (ja) | 抗mct1抗体およびその使用 | |
AU757961B2 (en) | Anti-Fas antibodies | |
AU734758B2 (en) | Anti-fas antibodies | |
AU736287B2 (en) | Humanized anti-human Fas antibody | |
CA2458993A1 (en) | A method for the treatment or prevention of bone erosion | |
JP2001039892A (ja) | 抗Fas抗体を含有する医薬組成物 | |
JP2003146903A (ja) | 骨破壊の治療又は予防剤組成物 | |
JP3444585B2 (ja) | 抗Fas抗体 | |
AU2002328084A1 (en) | A method for the treatment or prevention of bone erosion | |
JP2000169393A (ja) | 抗Fas抗体を含有する医薬 | |
JP2000166574A (ja) | ヒト化抗Fas抗体 | |
JP2001342149A (ja) | ヒト化抗Fas抗体を含有する医薬 | |
JP2001342148A (ja) | ヒト化抗Fas抗体を含有する医薬 | |
JP2000166573A (ja) | ヒト化抗Fas抗体 | |
JP2004000228A (ja) | 抗Fas抗体 | |
MXPA98002536A (en) | Antibodies anti- | |
CZ9903452A3 (cs) | Polidštěná molekula typu protilátky proti FAS, molekula typu protilátky s vybraným jedním nebo více těžkými řetězci a lehkými řetězci, profylaktický a léčebný přípravek, DNA kódující protilátku, rekombinantní DNA vektor, transformovaná hostitelská buňka, způsob výroby protilátky proti FAS, transformační kmen E. COLI, polypeptid, jeho kódující DNA, rekombinantní DNA vektor a transformovaná hostitelská buňka |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU BR CA CN CZ HU ID IL IN KR MX NO NZ PL RU TR US ZA |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: IN/PCT/2001/1204/KOL Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000931546 Country of ref document: EP Ref document number: 515598 Country of ref document: NZ Ref document number: 09989620 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2373992 Country of ref document: CA Ref document number: 2373992 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: PV2001-4181 Country of ref document: CZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001/03396 Country of ref document: TR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020017015062 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2001/012206 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 49486/00 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 008107807 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 1020017015062 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2000931546 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: PV2001-4181 Country of ref document: CZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 49486/00 Country of ref document: AU |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1020017015062 Country of ref document: KR |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000931546 Country of ref document: EP |
|
WWR | Wipo information: refused in national office |
Ref document number: PV2001-4181 Country of ref document: CZ |